NEXTBio Capital Management LP Purchases Shares of 752,631 Compass Pathways PLC Sponsored ADR $CMPS

NEXTBio Capital Management LP purchased a new stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 752,631 shares of the company’s stock, valued at approximately $5,193,000. Compass Pathways makes up 3.0% of NEXTBio Capital Management LP’s portfolio, making the stock its 13th biggest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company purchased a new position in Compass Pathways in the 4th quarter valued at approximately $96,000. Kalehua Capital Management LLC purchased a new position in Compass Pathways in the 4th quarter valued at approximately $5,656,000. Siren L.L.C. purchased a new position in Compass Pathways in the 4th quarter valued at approximately $6,900,000. Conservest Capital Advisors Inc. boosted its position in Compass Pathways by 24.6% in the 4th quarter. Conservest Capital Advisors Inc. now owns 25,363 shares of the company’s stock valued at $175,000 after buying an additional 5,000 shares during the period. Finally, Brooklyn Investment Group purchased a new stake in shares of Compass Pathways during the 4th quarter worth $134,000. Hedge funds and other institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $12.08 on Friday. The company has a 50-day simple moving average of $9.59 and a 200-day simple moving average of $7.60. Compass Pathways PLC Sponsored ADR has a one year low of $2.25 and a one year high of $14.76. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -3.83 and a beta of 2.50.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. On average, analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 EPS for the current year.

Analysts Set New Price Targets

CMPS has been the subject of several recent analyst reports. UBS Group set a $18.00 price objective on shares of Compass Pathways in a research report on Thursday, May 7th. Royal Bank Of Canada lifted their price objective on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, May 14th. Wall Street Zen raised shares of Compass Pathways from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Wolfe Research started coverage on Compass Pathways in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, Canaccord Genuity Group dropped their price objective on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.36.

Compass Pathways Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.